Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.
about
Trial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyIn situ immunization via non-surgical ablation to prevent local and distant tumor recurrence.Oncolytic adenoviruses: A thorny path to glioma cureImmunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.Role of NK cells in immunotherapy and virotherapy of solid tumors.Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines.Oncolytic virotherapy for urological cancers.Oncolytic Immunotherapy for Treatment of Cancer.Recent advances in oncolytic adenovirus therapies for cancer.Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer.Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: First evidence in preclinical hepatocellular carcinoma.Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts.Designer Oncolytic Adenovirus: Coming of Age.Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
P2860
Q27021951-F474F1CC-E9B9-4874-9928-448311FC25D9Q28072347-B50E9E08-7546-4EBB-B20F-02D214B1DC7BQ28084489-3F0C621C-61BD-4A33-8386-A7F34C6E146BQ34475389-BA5832A8-61AF-4B13-B633-73515271B3F0Q35077747-4C9E7BB2-A53B-4CB2-9D63-2D4CF15FF691Q35201826-C3E9912A-8955-4735-8C52-F0E34D56C77BQ38575116-9CB44F1E-749B-4B50-8F29-70E5F80D7D9AQ38654668-C0755B1A-B6E3-4C2B-8868-9ADB79C72095Q38752688-C9F9F9E4-C50B-47C9-AAA9-8B9CE497007DQ38829316-4BB69D4B-ECAF-485B-9B75-9ADB6D3A4840Q38842126-1E385DFB-0B6D-47D4-B5B7-77E55028DC93Q38848223-A2C7CF5D-3665-48E2-B56B-29914D1F34CEQ38886593-8DF4C829-7E7F-4DA3-998C-8441A370C3B5Q38920828-2212AED3-9579-45BC-8676-CF2C959F472AQ45872155-A66EB2B1-9C19-4D79-9349-1E1735246657Q53883435-14A4218D-4FD4-460D-B0BE-74D6E61CC207Q55467684-41CB7789-7E0F-4584-AE4F-BD902D64588CQ55509278-888F2CAD-F617-4A75-8A7A-78FE27FCF7DC
P2860
Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of oncolytic adenovir ...... ical model of prostate cancer.
@en
Efficacy of oncolytic adenovir ...... ical model of prostate cancer.
@nl
type
label
Efficacy of oncolytic adenovir ...... ical model of prostate cancer.
@en
Efficacy of oncolytic adenovir ...... ical model of prostate cancer.
@nl
prefLabel
Efficacy of oncolytic adenovir ...... ical model of prostate cancer.
@en
Efficacy of oncolytic adenovir ...... ical model of prostate cancer.
@nl
P2093
P2860
P921
P356
P1433
P1476
Efficacy of oncolytic adenovir ...... ical model of prostate cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2013.40
P577
2013-07-11T00:00:00Z